ABSTRACT
Objective Screening for genital infection (GI), bacterial vaginosis (BV), sexually transmitted infection (STI) and asymptomatic carriage of group B streptococcus (GBS) in pregnant women is a common reason for medical appointments. Objectives were first to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling to screen for GIs, bacterial vaginosis (BV), STIs, and GBS asymptomatic carriage in pregnant women; second to determine the feasibility of vaginal self-sampling.
Methods Vaginal self-sampling (VSS) and vaginal/cervical classical sampling (VCS) of 1027 women were collected by health care professionals and simultaneously carried out on each patient. Bacterial infection, yeast infection, Chlamydia trachomatis, Neisseria gonorrhoea, Mycoplasma genitalium, Trichomonas vaginalis and Herpes simplex virus types were systematically screened in both paired VSS and VCS samples.
Results Statistical tests supported the non-inferiority of VSS compared with VCS. Agreements between VCS and VSS remained high regardless of the type of studied infection. VSS had successful diagnostic performances, especially for Predictive negative value (PNV) (over 90%) for all studied infections. Most participants (84%) recommended the use of VSS.
Conclusions This study remains the most exhaustive in screening for GI, BV, STI agents and asymptomatic GBS carriage. Given its efficacy and acceptability, VSS seems to be a viable alternative to classic physician sampling among women in the general population. This study provides evidence that vaginal self-sampling can be used as a universal specimen for detection of lower genital tract infections in women.
Study Identification number ID-RCB 2014-A01250-4
- Vaginal self-sampling
- STI
- genital infection
- Group B streptococcus
- gynaecological monitoring
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ID-RCB 2014-A01250-4
Funding Statement
This work was supported by European Alphabio Laboratory and European Hospital of Marseille and two industrial companies, Roche Molecular Systems, Inc., and BioMerieux, for providing reagents. Roche Molecular Systems, Inc., supported Claire Camus for the preliminary presentation at the ECCMID congress 2017. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing the report. The corresponding author had full access to all study data and had final responsibility to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This biomedical clinical study was authorised by the French competent authority (ANSM, www.ansm.sante.fr) and received the agreement of an ethics committee (CPP Sud Mediterranee I). The French national identification number of the study is ID-RCB 2014-A01250-47.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
FUNDING: This work was supported by European Alphabio Laboratory and European Hospital of Marseille and two industrial companies, Roche Molecular Systems, Inc., and BioMérieux, for providing reagents. Roche Molecular Systems, Inc., supported Claire Camus for the preliminary presentation at the ECCMID congress 2017. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing the report. The corresponding author had full access to all study data and had final responsibility to submit for publication.
COMPETING INTEREST STATEMENT: All authors have completed the Unified Competing Interest form and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.
TRANSPARENCY DECLARATION: The manuscript is an honest, accurate, and transparent account of the study being reported. No important aspects of the study have been omitted; and any discrepancies from the study as planned have been explained.
Data Availability
Data will be available to researchers who provide a methodologically sound proposal. Requests should be addressed by email to g.penaranda{at}alphabio.fr
